|
|
|
|
||
Re: were the results that bad? It's hard to put a realistic value on biotech companies without any earnings. Just pulling numbers from dark smelly locations. Take a look at the range for Alnylam, from $78 to $200. And really, either of those are possible over the next 12 months. |
return to message board, top of board |